Virtual Pharmacy Attempts Move Into U.S. IBS Market

AGI Therapeutics is a small company of just 10 employees. However, this tiny Ireland-based pharmaceuticals company is tackling a big project: producing a drug that will treat IBS for the U.S. market. AGI’s philosophy is to seek alternative uses for drugs that are already on the market, rather than developing new drugs. Arverapamil, the drug AGI is currently testing for IBS, was approved as a cardiac drug in the past. AGI’s scientists have isolated the part of the molecule that causes constipation in heart patients and are currently in Phase III testing. The small company is able produce in volume because they outsource most of their work and use drugs that have already been approved by the FDA., September 20, 2007
2008-01-10 11:02:59

NTOKarun Upwork